Skip to main content

Monopar Therapeutics

MNPR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001645469

In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Monopar Therapeutics changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of MNPR: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders3543+8
Shares2.89M3.18M+290.5K (+10.1%)
Value$109.4M$113.3M+$3.93M (+3.6%)

New holders (19)

Institutions that held Monopar Therapeutics at the end of Q2 2025 but not at the end of Q1 2025.

Sold out (11)

Institutions that held Monopar Therapeutics at the end of Q1 2025 and filed for Q2 2025 without it.

Institutions that sold out of MNPR in Q2 2025
InstitutionShares, Q1 2025Value, Q1 2025
Marshall Wace, LLP25,988$946.2K
Goldman Sachs Group Inc18,480$672.9K
Jane Street Group, LLC10,357$377.1K
Omers Administration Corp9,000$327.7K
HRT Financial LP8,228$299.0K
Balyasny Asset Management LLC6,141$223.6K
Ikarian Capital, LLC5,908$215.1K
Point72 Asia (Singapore) Pte. Ltd.1,761$64.1K
Tower Research Capital LLC (TRC)303$11.0K
Point72 (DIFC) Ltd196$7.13K
Federation des caisses Desjardins du Quebec16$583